Nuvilex’s Subsidiary, Austrianova Singapore, to Provide Confirmatory Findings From Additional Pancreatic Cancer Trial …

SILVER SPRING, Md., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today that Austrianova Singapore Pte Ltd (ASPL) will reveal confirmatory findings from a second phase 2 pancreatic cancer clinical trial that used the encapsulated cytochrome P450 expressing cells followed by chemotherapy to treat pancreatic cancer at the International Society for Cell and Gene Therapy (ISCGT) meeting next week.

ASPL's Chief Operating Officer, Dr John Dangerfield, will be presenting the clinical data at the upcoming ISCGT meeting in Singapore, October 4-7. The ISCGT has previously organized numerous meetings in the US, England, France, Germany, Italy, Ireland, China, India and Egypt. The ISCGT works in close collaboration with national societies and organizations, as well as local clinicians, to promote cell and gene therapies for use in cancer therapy advancement and treatment. Council members of the ISCGT include leading experts and peers that have made major contributions to advance cell and gene therapies.

Dr. Brian Salmons, CEO of ASPL stated, "We determined that the ISCGT would be an important forum for presenting this additional data. The value for bringing this to ISCGT is a result of how they have been championing major developments in cell and gene therapy based approaches to treat cancer over the past several years. We are very pleased to have Dr. Dangerfield representing us as a speaker at this year's conference and presenting this important advancement to our work."

Dr. Robert F. Ryan, CEO of Nuvilex said, "The most important aspect of what will be presented at ISCGT is that safety and mean survival pancreatic cancer trial data being shown has not previously appeared in the public domain. Therefore, we are very pleased that this data will be shown at this conference. The data that Dr. Dangerfield will present confirms and extends the previous clinical trial results - namely that our encapsulated cell therapy, when used in combination with the appropriate chemotherapy, is safe, well-tolerated and efficacious for treating pancreatic cancer."

About Nuvilex

Nuvilex, Inc. (NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Substantial progress in multiple areas will be providing the Company with increased potential and we look forward to bringing those forward shortly. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

See the original post here:
Nuvilex's Subsidiary, Austrianova Singapore, to Provide Confirmatory Findings From Additional Pancreatic Cancer Trial ...